BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30362811)

  • 1. Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies.
    Korytowsky B; Radtchenko J; Nwokeji ED; Tuell KW; Kish JK; Feinberg BA
    Am J Manag Care; 2018 Oct; 24(20 Suppl):S439-S447. PubMed ID: 30362811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.
    Abraham P; Kish JK; Korytowsky B; Radtchenko J; Singh P; Shaw J; Feinberg B
    J Med Econ; 2020 Feb; 23(2):125-131. PubMed ID: 31581922
    [No Abstract]   [Full Text] [Related]  

  • 4. Better together? costs of first-line chemoimmunotherapy for advanced non-small cell lung cancer.
    Kish J; Liassou D; Hartman J; Lubinga SJ; Chopra D; Feinberg B
    Am J Manag Care; 2023 May; 29(5):e129-e135. PubMed ID: 37229786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.
    Skinner KE; Fernandes AW; Walker MS; Pavilack M; VanderWalde A
    J Med Econ; 2018 Feb; 21(2):192-200. PubMed ID: 29041833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
    Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship Between Guideline-Recommended Initiation of Therapy, Outcomes, and Cost for Patients with Metastatic Non-Small Cell Lung Cancer.
    Casebeer A; Antol DD; DeClue RW; Hopson S; Li Y; Khoury R; Michael T; Sehman M; Parikh A; Stemkowski S; Bunce M
    J Manag Care Spec Pharm; 2018 Jun; 24(6):554-564. PubMed ID: 29799325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
    Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
    PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
    J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
    Nadler E; Forsyth M; Satram-Hoang S; Reyes C
    J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
    Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
    Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
    Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
    Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
    PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
    J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer.
    Cohen JT; Lin PJ; Sheinson DM; Wong WB; Wu N; Yim YM; Ramsey SD
    J Oncol Pract; 2019 Nov; 15(11):e948-e956. PubMed ID: 31513478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
    Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
    J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
    Hornberger J; Hirsch FR; Li Q; Page RD
    Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
    Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
    Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.